APOE2 lowers Alzheimer’s disease (AD) risk; unfortunately, the mechanism remains poorly understood and the use of mice models is problematic as APOE2 homozygosity is associated with hyperlipidemia. In this study, we developed mice that are heterozygous for APOE2 and APOE3 or APOE4 and overexpress amyloid-β peptide (Aβ) (EFAD) to evaluate the effect of APOE2 dosage on Aβ pathology. We found that heterozygous mice do not exhibit hyperlipidemia. Hippocampal but not cortical levels of soluble Aβ42 followed the order E2/2FAD > E2/3FAD≤E3/3FAD and E2/2FAD > E2/4FAD < E4/4FAD without an effect on insoluble Aβ42. These findings offer initial insights on the impact of APOE2 on Aβ pathology.
CorderEH, SaunderSM, RischNJ, StrittmatterWJ, SchmechelDE, GaskellPCJr, RimmlerJB, LockePA, ConneallyPM, SchmaderKE, SmallGW, RosesAD, HainesJL, Pericak-VanceMA (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet7, 180–184.
2.
FarrerLA, CupplesLA, HainesJL, HymanB, KukullWA, MayeuxR, MyersRH, Pericak-VanceMA, RischN, van DuijnCM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA278, 1349–1356.
ShinoharaM, KanekiyoT, YangL, LinthicumD, ShinoharaM, FuY, PriceL, Frisch-DaielloJL, HanX, FryerJD, BuG (2016) APOE2 eases cognitive decline during Aging: Clinical and preclinical evaluations. Ann Neurol79, 758–774.
6.
LiZ, ShueF, ZhaoN, ShinoharaM, BuG (2020) APOE2: Protective mechanism and therapeutic implications for Alzheimer’s disease. Mol Neurodegener15, 63.
7.
BerlauDJ, CorradaMM, HeadE, KawasCH (2009) APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology72, 829–834.
NagyZ, EsiriMM, JobstKA, JohnstonC, LitchfieldS, SimE, SmithAD (1995) Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer’s disease. Neuroscience69, 757–761.
10.
NelsonPT, PiousNM, JichaGA, WilcockDM, FardoDW, EstusS, RebeckGW (2013) APOE-epsilon2 and APOE-epsilon4 correlate with increased amyloid accumulation in cerebral vasculature. J Neuropathol Exp Neurol72, 708–715.
11.
OhmTG, ScharnaglH, MarzW, BohlJ (1999) Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer’s disease-related lesions. Acta Neuropathol98, 273–280.
12.
SullivanPM, MezdourH, QuarfordtSH, MaedaN (1998) Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J Clin Invest102, 130–135.
13.
HopkinsPN, BrintonEA, NanjeeMN (2014) Hyperlipoproteinemia type 3: The forgotten phenotype. Curr Atheroscler Rep16, 440.
14.
SchillingS, TzourioC, SoumareA, KaffashianS, DartiguesJF, AncelinML, SamieriC, DufouilC, DebetteS (2017) Differential associations of plasma lipids with incident dementia and dementia subtypes in the 3C Study: A longitudinal, population-based prospective cohort study. PLoS Med14, e1002265.
15.
AnsteyKJ, Ashby-MitchellK, PetersR (2017) Updating the evidence on the association between serum cholesterol and risk of late-life dementia: Review and meta-analysis. J Alzheimers Dis56, 215–228.
16.
HofmanA, OttA, BretelerMM, BotsML, SlooterAJ, van HarskampF, van DuijnCN, Van BroeckhovenC, GrobbeeDE (1997) Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet349, 151–154.
17.
WingoAP, VattathilSM, LiuJ, FanW, CutlerDJ, LeveyAI, SchneiderJA, BennettDA, WingoTS (2022) LDL cholesterol is associated with higher AD neuropathology burden independent of APOE. J Neurol Neurosurg Psychiatry93, 930–938.
18.
ChenY, LimP, RogersKA, RuttBK, RonaldJA (2018) In Vivo MRI of amyloid plaques in a cholesterol-fed rabbit model of Alzheimer’s disease. J Alzheimers Dis64, 911–923.
19.
ShieFS, JinLW, CookDG, LeverenzJB, LeBoeufRC (2002) Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport13, 455–459.
20.
UmedaT, TomiyamaT, KitajimaE, IdomotoT, NomuraS, LambertMP, KleinWL, MoriH (2012) Hypercholesterolemia accelerates intraneuronal accumulation of Abeta oligomers resulting in memory impairment in Alzheimer’s disease model mice. Life Sci91, 1169–1176.
21.
YoumansKL, TaiLM, Nwabuisi-HeathE, JungbauerL, KanekiyoT, GanM, KimJ, EimerWA, EstusS, RebeckGW, WeeberEJ, BuG, YuC, LaduMJ (2012) APOE4-specific changes in abeta accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem287, 41774–41786.
22.
LiuDS, PanXD, ZhangJ, ShenH, CollinsNC, ColeAM, KosterKP, Ben AissaM, DaiXM, ZhouM, TaiLM, ZhuYG, LaDuM, ChenXC (2015) APOE4 enhances age-dependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice. Mol Neurodegener10, 7.
23.
TaiLM, BaluD, Avila-MunozE, AbdullahL, ThomasR, CollinsN, Valencia-OlveraAC, LaDuMJ (2017) EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer’s disease. J Lipid Res58, 1733–1755.
24.
BaluD, KarstensAJ, LoukenasE, Maldonado WengJ, YorkJM, Valencia-OlveraAC, LaDuMJ (2019) The role of APOE in transgenic mouse models of AD. Neurosci Lett707, 134285.
25.
BaluD, Valencia-OlveraA, IslamZ, MeliczarekC, HansenA, Perez RamosT, YorkJ, LaDuMJ, TaiLM (2023) APOE genotype and sex modulate Alzheimer’s disease pathology in aged EFAD transgenic mice. Front Aging Neurosci15, 1279343.
26.
AbdullahL, EvansJE, EmmerichT, CrynenG, ShackletonB, KeeganAP, LuisC, TaiL, LaDuMJ, MullanM, CrawfordF, BachmeierC (2017) APOE epsilon4 specific imbalance of arachidonic acid and docosahexaenoic acid in serum phospholipids identifies individuals with preclinical mild cognitive impairment/Alzheimer’s disease. Aging (Albany NY)9, 964–985.
27.
CacciottoloM, MorganTE, FinchCE (2021) Age, sex, and cerebral microbleeds in EFAD Alzheimer disease mice. Neurobiol Aging103, 42–51.
28.
ChristensenA, PikeCJ (2018) APOE genotype affects metabolic and Alzheimer-related outcomes induced by Western diet in female EFAD mice. FASEB J33, 4054–4066.
29.
KunzlerJ, YoumansKL, YuC, LaduMJ, TaiLM (2014) APOE modulates the effect of estrogen therapy on Abeta accumulation EFAD-Tg mice. Neurosci Lett560, 131–136.
30.
Maldonado WengJ, ParikhI, NaqibA, YorkJ, GreenSJ, EstusS, LaDuMJ (2019) Synergistic effects of APOE and sex on the gut microbiome of young EFAD transgenic mice. Mol Neurodegener14, 47.
31.
StephenTL, CacciottoloM, BaluD, MorganTE, LaDuMJ, FinchCE, PikeCJ (2019) APOE genotype and sex affect microglial interactions with plaques in Alzheimer’s disease mice. Acta Neuropathol Commun7, 82.
32.
TaxierLR, PhilippiSM, YorkJM, LaDuMJ, FrickKM (2022) APOE4 genotype or ovarian hormone loss influence open field exploration in an EFAD mouse model of Alzheimer’s disease. Horm Behav140, 105124.
UlrichJD, BurchettJM, RestivoJL, SchulerDR, VerghesePB, MahanTE, LandrethGE, CastellanoJM, JiangH, CirritoJR, HoltzmanDM (2013) In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol Neurodegener8, 13.
39.
NaiduA, CatalanoR, BalesK, WuS, PaulSM, CordellB (2001) Conversion of brain apolipoprotein E to an insoluble form in a mouse model of Alzheimer disease. Neuroreport12, 1265–1270.
40.
BalesKR, LiuF, WuS, LinS, KogerD, DeLongC, HansenJC, SullivanPM, PaulSM (2009) Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci29, 6771–6779.
41.
BalesKR, VerinaT, CumminsDJ, DuY, DodelRC, SauraJ, FishmanCE, DeLongCA, PiccardoP, PetegniefV, GhettiB, PaulSM (1999) Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A96, 15233–15238.
42.
KuoYM, CrawfordF, MullanM, KokjohnTA, EmmerlingMR, WellerRO, RoherAE (2000) Elevated A beta and apolipoprotein E in A betaPP transgenic mice and its relationship to amyloid accumulation in Alzheimer’s disease. Mol Med6, 430–439.
43.
IgetaY, KawarabayashiT, SatoM, YamadaN, MatsubaraE, IshiguroK, KanaiM, TomidokoroY, OsugaJ, OkamotoK, HiraiS, ShojiM (1997) Apolipoprotein E accumulates with the progression of A beta deposition in transgenic mice. J Neuropathol Exp Neurol56, 1228–1235.
44.
MahleyRW, HuangY, RallSCJr (1999) Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res40, 1933–1949.
45.
EvansD, BeilFU, AberleJ (2013) Resequencing the APOE gene reveals that rare mutations are not significant contributory factors in the development of type III hyperlipidemia. J Clin Lipidol7, 671–674.
46.
Rall SCJr, WeisgraberKH, InnerarityTL, MahleyRW (1982) Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci U S A79, 4696–4700.
47.
DongLM, ParkinS, TrakhanovSD, RuppB, SimmonsT, ArnoldKS, NewhouseYM, InnerarityTL, WeisgraberKH (1996) Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat Struct Biol3, 718–722.
48.
WeisgraberKH, InnerarityTL, MahleyRW (1982) Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem257, 2518–2521.
49.
MahleyRW, WeisgraberKH, HuangY (2009) Apolipoprotein E: Structure determines function, from atherosclerosis toAlzheimer’s disease to AIDS. J Lipid Res50, S183–S188.
50.
ChappellDA (1988) Pre-beta-very low density lipoproteins as precursors of beta-very low density lipoproteins. A model for the pathogenesis of familial dysbetalipoproteinemia (type III hyperlipoproteinemia). J Clin Invest82, 628–639.
51.
KuhelDG, KonaniahES, BasfordJE, McVeyC, GoodinCT, ChatterjeeTK, WeintraubNL, HuiDY (2013) Apolipoprotein E2 accentuates postprandial inflammation and diet-induced obesity to promote hyperinsulinemia in mice. Diabetes62, 382–391.
52.
LeeSJ, KimJH, KimJH, ChungMJ, WenQ, ChungH, KimKW, YuYS (2007) Human apolipoprotein E2 transgenic mice show lipid accumulation in retinal pigment epithelium and altered expression of VEGF and bFGF in the eyes. J Microbiol Biotechnol17, 1024–1030.
53.
LimYY, MorminoEC; Alzheimer’s Disease Neuroimaging Initiative (2017) APOE genotype and early beta-amyloid accumulation in older adults without dementia. Neurology89, 1028–1034.
54.
GoldbergTE, HueyED, DevanandDP (2020) Association of APOE e2 genotype with Alzheimer’s and non-Alzheimer’s neurodegenerative pathologies. Nat Commun11, 4727.
55.
PankiewiczJE, GuridiM, KimJ, AsuniAA, SanchezS, SullivanPM, HoltzmanDM, SadowskiMJ (2014) Blocking the apoE/Abeta interaction ameliorates Abeta-related pathology in APOE epsilon2 and epsilon4 targeted replacement Alzheimer model mice. Acta Neuropathol Commun2, 75.
56.
FaganAM, WatsonM, ParsadanianM, BalesKR, PaulSM, HoltzmanDM (2002) Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer’s disease. Neurobiol Dis9, 305–318.
HuynhTV, WangC, TranAC, TaborGT, MahanTE, FrancisCM, FinnMB, SpellmanR, ManisM, TanziRE, UlrichJD, HoltzmanDM (2019) Lack of hepatic apoE does not influence early Abeta deposition: Observations from a new APOE knock-in model. Mol Neurodegener14, 37.
60.
MannKM, ThorngateFE, Katoh-FukuiY, HamanakaH, WilliamsDL, FujitaS, LambBT (2004) Independent effects of APOE on cholesterol metabolism and brain Abeta levels in an Alzheimer disease mouse model. Hum Mol Genet13, 1959–1968.
61.
XuF, VitekMP, ColtonCA, PrevitiML, DavisJ, Van NostrandWE (2012) Human apolipoprotein E2 promotes parenchymal amyloid deposition and neuronal loss in vasculotropic mutant amyloid-beta protein Tg-SwDI mice. J Alzheimers Dis31, 359–369.
62.
HoltzmanDM, BalesKR, TenkovaT, FaganAM, ParsadanianM, SartoriusLJ, MackeyB, OlneyJ, McKeelD, WozniakD, PaulSM (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A97, 2892–2897.
IrizarryMC, CheungBS, RebeckGW, PaulSM, BalesKR, HymanBT (2000) Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid beta-peptide deposition in homozygous APP(V717F) transgenic mice. Acta Neuropathol100, 451–458.
65.
DeMattosRB, CirritoJR, ParsadanianM, MayPC, O’DellMA, TaylorJW, HarmonyJA, AronowBJ, BalesKR, PaulSM, HoltzmanDM (2004) ApoE and clusterin cooperatively suppress abeta levels and deposition. Evidence that ApoE regulates extracellular abeta metabolism In Vivo. Neuron41, 193–202.
66.
HudryE, KlicksteinJ, CannavoC, JacksonR, MuzikanskyA, GandhiS, UrickD, SargentT, WrobleskiL, RoeAD, HouSS, KuchibhotlaKV, BetenskyRA, Spires-JonesT, HymanBT (2019) Opposing Roles of apolipoprotein E in aging and neurodegeneration. Life Sci Alliance2, e201900325.
67.
JacksonRJ, KeiserMS, MeltzerJC, FykstraDP, DierksmeierSE, MelloniA, NakajimaT, TecedorL, RanumPT, CarrellE, ChenY, HoltzmanDM, DavidsonBL, HymanBT (2023) APOE2 gene therapy reduces amyloid deposition, and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease. bioRxiv, doi: 10.1101/2023.08.14.552850 [Preprint]. Posted August 16, 2023.
68.
AroldS, SullivanP, BilousovaT, TengE, MillerCA, PoonWW, VintersHV, CornwellLB, SaingT, ColeGM, GylysKH (2012) Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer’s disease and apoE TR mouse cortex. Acta Neuropathol123, 39–52.
69.
KleinRC, AchesonSK, MaceBE, SullivanPM, MooreSD (2014) Altered neurotransmission in the lateral amygdala in aged human apoE4 targeted replacement mice. Neurobiol Aging35, 2046–2052.
70.
KleinRC, MaceBE, MooreSD, SullivanPM (2010) Progressive loss of synaptic integrity in human apolipoprotein E4 targeted replacement mice and attenuation by apolipoprotein E2. Neuroscience171, 1265–1272.
71.
TsukamotoK, SmithP, GlickJM, RaderDJ (1997) Liver-directed gene transfer and prolonged expression of three major human ApoE isoforms in ApoE-deficient mice. J Clin Invest100, 107–114.
72.
ShinoharaM, KanekiyoT, TachibanaM, KurtiA, ShinoharaM, FuY, ZhaoJ, HanX, SullivanPM, RebeckGW, FryerJD, HeckmanMG, BuG (2020) APOE2 is associated with longevity independent of Alzheimer’s disease. Elife9, e62199.
73.
GetzGS, ReardonCA (2016) ApoE knockout and knockin mice: The history of their contribution to the understanding of atherogenesis. J Lipid Res57, 758–766.
74.
HinderLM, VincentAM, HayesJM, McLeanLL, FeldmanEL (2013) Apolipoprotein E knockout as the basis for mouse models of dyslipidemia-induced neuropathy. Exp Neurol239, 102–110.
75.
Valencia-OlveraAC, BaluD, FaulkN, AmiridisA, WangY, PhamC, Avila-MunozE, YorkJM, ThatcherGRJ, LaDuMJ (2023) Inhibition of ACAT as a therapeutic target for Alzheimer’s disease is independent of ApoE4 lipidation. Neurotherapeutics20, 1120–1137.
76.
LaDuMJ, MunsonGW, JungbauerL, GetzGS, ReardonCA, TaiLM, YuC (2012) Preferential interactions between ApoE-containing lipoproteins and Abeta revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift. Biochim Biophys Acta1821, 295–302.
77.
YoumansKL, LeungS, ZhangJ, MausE, BaysacK, BuG, VassarR, YuC, LaduMJ (2011) Amyloid-beta42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations. J Neurosci Methods196, 51–59.
